Roche announced that the European Commission has approved PiaSky, a novel recycling monoclonal antibody that inhibits the complement protein C5, for adults and adolescents with paroxysmal nocturnal haemoglobinuria, or PNH, who are either new to, or have been previously treated with C5 inhibitors. “PiaSky is the first monthly subcutaneous treatment for PNH in the European Union, with the option to self-administer following adequate training. It provides an alternative option to current C5 inhibitors that require regular intravenous infusions, which could help to reduce treatment burden and disruption to the lives of people with PNH and their caregivers,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
- Roche announces it will support response to mpox global health emergency
- Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak
- Craig-Hallum starts Lineage Cell Therapeutics at Buy on OpRegen opportunity
- Lixte Biotechnology provides update on recent activities, developments